Replimune Group Class Action Lawsuits
Analysis based on 36 articles · First reported Jul 25, 2025 · Last updated Sep 03, 2025
The multiple class action lawsuits against Replimune Group, Inc. are expected to negatively impact its stock price and investor confidence. The United States — Food and Drug Administration's rejection of Replimune Group's drug application has already caused a significant drop in its stock, leading to substantial investor losses.
Replimune Group, Inc. is facing multiple class action securities lawsuits from law firms including Rosen Law Firm, Levi & Korsinsky, and Faruqi & Faruqi. These lawsuits allege that Replimune Group made false and misleading statements regarding the prospects of its IGNYTE trial. The United States — Food and Drug Administration deemed the IGNYTE trial inadequate and not well-controlled, leading to the rejection of Replimune Group's Biologics License Application for RP1 in treating advanced melanoma. This news caused Replimune Group's stock to plummet over 73% on July 22, 2025, resulting in significant investor losses. Investors who purchased Replimune Group securities between November 22, 2024, and July 21, 2025, are encouraged to join the class actions, with a lead plaintiff deadline of September 22, 2025.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard